Main Page
Faculty Deanship
Dean
Health Empowerment Unit
Strategic Planning Unit
Development and Quality Unit
Medical and Bioethics Unit
Vice Dean for Graduate Studies and Research
Vice Dean for Female Section
Vice dean for Academic Affairs
Examination and Assessment Unit
Internship and Alumni Unit
Student Research Unit
E-learning Unit
Student Mentoring and Support Unit
Community Service Unit
Talent and Creativity Care Unit
Continuing Education Unit
Neuroscience Research Unit
Vice Deanship of Clinical Affairs / Administration
Organizational Structure
Departments
Basic Sciences
Department of Anatomy
Department of Pharmacology
Department of Pathology
Department of Microbiology and Medical Parasitolog
Deparment of Clinical Biochemistry
Department of Physiology
Department of Medical Genetics
Clinical Sciences
Department of Otorhinolaryngology
Department of Obstetrics and Gynecology
Department of Hematology
Department of Medical Education
Department of Anesthesia
Department of Family Medicine
Department of Community Medicine
Department of Surgery
Department of Orthopedic Surgery
Department of ophthalmology
Department of Radiology
Department of Internal Medicine
Department of Pediatrics
Department of Emergency Medicine
Department of Urology
Department of Dermatology
Latest News
عربي
English
About
Admission
Academic
Research and Innovations
University Life
E-Services
Search
Faculty of Medicine
Document Details
Document Type
:
Article In Journal
Document Title
:
Eighteen-Month Follow-up of Glipizide and Human Insulin Combination in the Treatment of Type II Diabetes Mellitus
Eighteen-Month Follow-up of Glipizide and Human Insulin Combination in the Treatment of Type II Diabetes Mellitus
Subject
:
Endocrinology
Document Language
:
English
Abstract
:
This study reports a follow up of 29 Type II Diabetic patients with secondary drug failure treated by a combination of Human Insulin and Glipizide. During their follow-up, Insulin therapy was instituted following discontinuation of the maximum permissible dose of sulphonylureas for variable periods of time and thereafter Glipizide was added to Insulin treatment. Their diabetic control was assessed by checking the fasting and 2hr postprandial venous blood glucose values, HbA1c and weight changes. These results were then compared in various phases of treatment, i.e. Phase I: Oral hypoglycemic agents, Phase II: Insulin alone (mean duration 2.55 ± 1.75 years), and Phase III: Human Insulin and Glipizide combination (mean duration 1.93 ± 0.72 years). It was found that patients in Phase III showed an overall improved glycemic control compared to Phase I and II. HbA1c dropped to 9.11±3.25 in Phase III compared to 11.13±2.75 in Phase II and 11.45±2.07 in Phase I. There was a weight gain of 3.66±6.69 kg in Phase II as compared to a net loss of 1.14±5.93 kg in Phase III. The mean daily requirement of Insulin in Phase II of 65.19 U decreased to 49.62 U in Phase III. No relationship was established between the initial high Body Mass Index and initial C-peptides of responders and non-responders to combination therapy. This study highlights the value of combination therapy of Glipizide plus Human Insulin in the control of diabetes after secondary failure in Type II diabetic patients
ISSN
:
1319-1004
Journal Name
:
Medical Science Journal
Volume
:
2
Issue Number
:
1
Publishing Year
:
1412 AH
1992 AD
Article Type
:
Article
Added Date
:
Sunday, August 30, 2009
Researchers
Researcher Name (Arabic)
Researcher Name (English)
Researcher Type
Dr Grade
Email
سراج ميره
Mira, Siraj
Investigator
Doctorate
حسان فطاني
Fatani, Hassan
Researcher
Doctorate
أحمد خان
Khan, Ahmed
Researcher
Doctorate
Files
File Name
Type
Description
29282.pdf
pdf
Back To Researches Page